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Abstract
Chronic kidney disease (CKD) is a complex disorder. As genome-wide association studies identified cubilin gene CUBN as a
locus for albuminuria, and urinary protein loss is a risk factor for progressive CKD, we tested the hypothesis that common
genetic variants in CUBN are associated with end-stage renal disease (ESRD) and proteinuria. First, a total of 1142 patients
with ESRD, admitted for renal transplantation, and 1186 donors were genotyped for SNPs rs7918972 and rs1801239 (case-
control study). The rs7918972 minor allele frequency (MAF) was higher in ESRD patients comparing to kidney donors,
implicating an increased risk for ESRD (OR 1.39, p= 0.0004) in native kidneys. Second, after transplantation recipients were
followed for 5.8 [3.8–9.2] years (longitudinal study) documenting ESRD in transplanted kidneys – graft failure (GF). During
post-transplant follow-up 92 (9.6%) cases of death-censored GF occurred. Donor rs7918972 MAF, representing genotype of
the transplanted kidney, was 16.3% in GF vs 10.7% in cases with functioning graft. Consistently, a multivariate Cox
regression analysis showed that donor rs7918972 is a predictor of GF, although statistical significance was not reached (HR
1.53, p= 0.055). There was no association of recipient rs7918972 with GF. Rs1801239 was not associated with ESRD or GF. In
line with an association with the outcome, donor rs7918972 was associated with elevated proteinuria levels cross-
sectionally at 1 year after transplantation. Thus, we identified CUBN rs7918972 as a novel risk variant for renal function loss
in two independent settings: ESRD in native kidneys and GF in transplanted kidneys.
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Introduction
Chronic kidney disease (CKD) is a complex multifactorial
disorder with an important genetic component [1–3]. A recent
genome-wide association study (GWAS) identified the cubilin gene
CUBN as a locus for albuminuria: a missense single-nucleotide
polymorphism (SNP) rs1801239 (Ile2984Val) in this gene was
associated with elevated urinary albumine-to-creatinine ratio and
microalbuminuria in both the general population and in diabetic
patients [4].
As albuminuria is a risk factor for progression of CKD up to end
stage renal disease (ESRD) [5], we hypothesized that genetic
variation in CUBN is associated with development of ESRD. To
test this hypothesis we genotyped patients with ESRD, admitted
for renal transplantation, with their donors as a control
population, for SNPs in the CUBN locus and followed the
recipients after transplantation documenting clinical parameters
and occurrence of graft failure (GF).
Two CUBN SNPs were genotyped in our study: the previously
published rs1801239 and a tagSNP rs7918972. The latter was
selected based on its linkage disequilibrium with 9 other SNPs thus
covering more variability in the locus and taking into account that
one of the linked polymorphisms is a coding missense variant
which might potentially be functional. Another selection criterion
was the minor allele frequency (MAF); we targeted a lower part
of the common variability range, with MAFs between 10 and
15%.
Within this cohort we performed essentially two independent
analyses: 1) ESRD patients admitted for renal transplantation
versus kidney donors (extreme case-control study) – to test for
association with ESRD in native kidneys; and 2) long-term post-
transplant follow-up for GF in the recipients (longitudinal study) –
for association with ESRD in the transplanted kidney.
We also tested association of the CUBN SNPs with 24-h total
urinary protein excretion as an intermediate phenotype.
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Materials and Methods
Study population
From all renal transplantations carried out in our center
between 1993 and 2008 we retrospectively selected 1142 first graft
recipients and 1186 donors for the present genetic study. The
exclusion criteria were: cases of re-transplantation, combined
kidney/pancreas or kidney/liver transplantation, technical prob-
lems, absence of DNA and loss of follow-up. A flowchart of the
study participants selection is shown in the Figure 1. After
transplantation the recipients were followed up and immunosup-
pression regimen, clinical and laboratory parameters, and time to
GF were documented. GF was defined as return to dialysis or re-
transplantation and was censored for death with a functioning
graft. Cases with post-transplant graft survival ,1 year were
excluded from the analyses, to decrease heterogeneity in the
sample, as graft loss ,1 year is to an important extent due to acute
complications, such as technical surgical problems, delayed graft
function and/or acute rejection episodes, whereas we wanted to
focus on the process of chronic transplant dysfunction. Donor and
recipient characteristics, transplantation-related parameters and
clinical data (24 h urinary protein excretion, blood pressure, renal
function) were retrieved from medical records. The Institutional
Review Board of the University Medical Center Groningen
approved the study protocol. Written informed consent was given
by all recipients and living donors. For deceased donors, with
research carried out after the organ removal and implantation, no
consent was required. According to Dutch law general consent for
organ donation and transplantation includes consent for research
projects. The study was conducted according to the principles of
the Declaration of Helsinki. All the genetic and clinical data were
anonymized prior to analyses.
DNA isolation, tagSNP selection and genotyping
DNA was extracted from peripheral whole blood (in recipients
and living donors) or lymph nodes/spleen lymphocytes (in
deceased donors) using a commercial kit following the manufac-
turer’s instructions, transferred into 2 ml Eppendorf tubes and
stored at 220uC. Absorbance at 260 nm was measured with
NanoDrop spectrophotometer (ND-1000, NanoDrop Technolo-
gies) and DNA concentration was calculated by the NanoDrop
nucleic acid application module. As a measure of DNA purity
260/280 and 260/230 absorbance ratios were assessed. Where
samples failed to meet the minimum DNA concentration and
purity recommended for Illumina genotyping, repeated isolation
attempts were made.
Two SNPs in the CUBN locus were genotyped: missense
(Ile2984Val) rs1801239 and rs7918972. The latter is a tagSNP in
the CUBN intron, which was selected using Genome Variation
Server v5.11 (Seattle SNPs Program for Genomic Applications).
This program utilizes the LDSelect algorithm [6]. All the SNPs
within the CUBN gene including 500 bases at the gene flanking
regions were submitted to the selection procedure. The following
parameter settings were used: HapMap-CEU population (unre-
lated only, no HapMap 3), monomorphic sites excluded, r2
threshold 0.8, minimal genotype coverage for tagSNPs 85%.
Further, for our study we considered SNPs with MAFs 10–15%,
tagging as many other variants as possible including the missense
ones. Rationale for the arbitrary MAF cut-off was based on the
general expectation that rarer variants have a slightly higher
likelihood to be causal and may confer stronger effects. At the
same time, as power to detect such effects depends on sample size,
we were constrained by the moderate sample size of our study.
That is why we set the cut-off in the range of 10–15%. Using these
settings, the SNP rs7918972 was the best tagSNP meeting all our
criteria (minimal MAF – 10%, maximal number of the tagged
SNPs – 9, tagging a missense variant) and therefore was ultimately
chosen for this study. This SNP is in strong linkage disequilibrium
with intronic SNPs rs4088454, rs7897625, rs7897716, rs7898076,
rs11254232, rs11254238, rs7897442, rs7897705 and missense
(Asn3552Lys) rs1801232, all of which map to the CUBN locus. The
LD structure of the studied CUBN SNPs is shown in the
Supplemental Figure S1.
Genotyping of the selected SNPs was performed using the
Illumina VeraCode GoldenGate assay kit (Illumina, San Diego,
CA, USA), according to the manufacturer’s instructions. Genotype
clustering and calling were performed using BeadStudio Software
(Illumina). In five individuals genotyping was unsuccessful.
Statistical analysis
Analyses were performed with PASW Statistics 18.0 (SPSS Inc.,
Chicago, IL) and PLINK v1.07 (S. Purcell, http://pngu.mgh.
harvard.edu/purcell/plink/) [7]. QUANTO v1.2.4 (http://hydra.
usc.edu/gxe/) and PASS v11 were used for power estimation.
PolyPhen2 [8] was used to predict functional consequences of the
missense SNP. The studied CUBN SNPs LD structure plot was
generated with SNAP v2.2 [9].
As a routine data quality control, alleles frequencies, Hardy-
Weinberg equilibrium and case/control differential missingness
were tested for. Subsequent statistical analyses were performed on
a final sample of 2323 subjects in a case-control design (1141
recipients vs 1182 donors) and 962 renal transplant recipients in a
longitudinal design. With two-sided p= 0.05, assuming an additive
genetic model and MAF of 10–15%, we had 57% and 99% power
to detect an OR of 1.2 and 1.4, respectively, in the ESRD case-
control analysis, and 43% and 87% power to detect a HR of 1.5
and 2.0, respectively, in the Cox regression analysis of graft
survival.
Genotype-phenotype associations were tested under an additive
genetic model and results (regression coefficients and p-values) are
reported per copy of the minor allele.
In the case-control analysis, the PLINK DFAM algorithm was
used to account for donor-recipient relatedness within living-donor
transplantation cases. Interaction between the SNPs was tested
with the PLINK –epistasis function which includes the interaction
term and the marginal effects of the SNPs into the interaction
model. Subsequently, stratified logistic regression analyses were
performed for each of the three groups of minor allele carriers of
both SNPs using the group of non-carriers as the reference.
For the longitudinal study we included cases with post-transplant
graft survival $1 year. The effect of SNPs on graft survival was
investigated with Kaplan-Meier and Cox regression analyses including
known predictors of GF (donor and recipient age and sex, donor type,
cold and warm ischemia times, immunosuppressive therapy).
Association between genotypes and 24 h urinary protein
excretion was studied cross-sectionally at 1 year after transplan-
tation assuming stable graft function at this time-point. As
proteinuria was considered a left-censored phenotype with 0
values in 24.4% of patients (due to the diagnostic assay detection
limit and rounding of routinely reported values), it was analyzed
with Tobit regression [10,11], both univariately and including
relevant covariates (age, sex, systolic and diastolic blood pressure).
Results
Main patients characteristics are presented in Table 1.
The overall minor allele frequency was 13.1% for rs7918972
and 12.5% for rs1801239. There was no deviation from Hardy-
CUBN as a Novel Locus for ESRD
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Weinberg equilibrium in controls (p=0.2908 for rs7918972;
p=0.4126 for rs1801239). The missing genotypic data fraction
was not different between cases and controls (p=1.000 and
p=0.625 for rs7918972 and rs1801239, respectively). There was
no linkage disequilibrium between rs7918972 and rs1801239
(r2 = 0.002, D9=0.059). The missense rs1801232 (Asn3552Lys),
tagged by rs7918972, was predicted to be benign by PolyPhen2:
score 0.011; sensitivity 0.96; specificity 0.72.
Case-control study: ESRD patients vs kidney donors
The minor allele frequency (MAF) for rs7918972 was signifi-
cantly higher in ESRD patients as compared to kidney donors,
implicating an increased risk of ESRD: OR [95% CI] 1.39 [1.16–
1.65], p=0.0004, in an additive model adjusted for age, sex and
case-control relatedness (Table 2); additional adjustment for
diabetes status did not change the results. There was no
association between rs7918972 genotype and any of the primary
diseases (etiology of ESRD). The MAF for rs7918972 was not
different between living and deceased donors and in the latter it
was not significantly associated with the cause of death (mortality
due to cerebro- or cardiovascular accident vs other reasons).
Genotype of rs1801239 was not associated with case/control status
or any of the other traits studied.
The effects of the two SNPs were not independent as a case-
control test for epistasis revealed an interaction between them
(p=5610210). A finer analysis showed that the rs7918972 minor
allele requires a copy of the rs1801239 minor allele to express its
risk phenotype (OR 3.15 [2.21–4.48], p=1.8610210), whereas the
minor allele of rs1801239 displays protective effect in the absence
of rs7918972 minor allele (OR 0.65 [0.52–0.81], p=1.761024)
[Table 3].
Longitudinal study: post-transplant follow-up
A total of 92 (9.6%) cases of death-censored GF occurred and
151 (15.8%) patients died with a functioning graft during a median
[IQR] of 5.8 [3.8–9.5] years of follow-up.
Donor MAF, representing genotype of the transplanted kidney,
was higher in subjects that suffered death-censored GF as
compared to cases with a functioning graft (16.3% vs 10.7%,
respectively). Kaplan-Meier survival analysis revealed worse graft
survival (p=0.067) for the carriers of the minor allele (Figure 2).
Consistently, a multivariate Cox regression analysis showed that
donor kidney rs7918972 is a predictor of GF yielding a HR of 1.53
Figure 1. A flowchart of the study participants selection.
doi:10.1371/journal.pone.0036512.g001
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[0.99–2.37], p=0.055, per copy of the minor allele, in a model
adjusted for donor and recipient age and sex, donor type (living vs
deceased), ischemia times, immunosuppressive drug use and acute
rejection episodes (Table 4). In contrast, recipient rs7918972 was
not associated with development of GF (HR 1.00, p=0.992).
Neither donor nor recipient rs1801239 was significantly associated
with GF. There was no statistically significant interaction between
the two SNPs in the longitudinal analysis of GF.
Neither donor nor recipient genotypes were significantly
associated with cardiovascular or all-cause mortality during post-
transplant follow-up.
We found donor rs7918972 to be associated with proteinuria
levels cross-sectionally at 1 year of post-transplant follow-up (beta
0.201, p=0.015) [Table 5]. No association between the SNPs and
renal function by measured GFR or creatinine clearance was
observed at the same time-point; however, donor rs7918972
showed a directionally consistent, although not statistically
significant, trend for association with an increased rate of GFR
decline (data not shown).
Discussion
In the present study we followed up the results of a recent
GWAS, which identified the cubilin gene CUBN as a locus for
albuminuria [4]. As albuminuria is an established risk factor for
progressive renal function loss, the GWAS findings raised the
hypothesis that genetic variation in the CUBN locus could be
associated with progressive renal function loss and finally end stage
renal disease. To test this hypothesis we studied the cited top SNP
as well as a tagSNP in CUBN in relation to final renal clinical
outcomes, namely ESRD in native kidneys and GF in the
transplanted kidney.
In a case-control design we studied rs7918972 and rs1801239
genotypes in ESRD patients versus kidney donors. The MAF for
rs7918972 was significantly higher in ESRD patients as compared
to kidney donors, imposing a 39% increased risk for ESRD per
copy of the minor allele. Follow-up data after transplantation
showed direction-consistent trend for an association between
donor kidney rs7918972 and development of GF in recipients.
Thus, the SNP in CUBN locus was associated with susceptibility to
develop ESRD in two settings, namely ESRD in native kidneys
and GF in transplanted kidneys.
Transplantation represents a unique setting, also from genetic
point view: an organ with its own genotype functions in an
organism with another genotype. We tested both donor and
recipient genotype for association with the renal outcome to
investigate whether it is the kidney genotype that determines its
own fate or it is the recipient genotype that influences function and
survival of the transplanted organ. This unique design is useful for
genetic research in nephrology as it enables discrimination
between the renal and extra-renal mechanisms [12].
In our study, it was donor rather than recipient CUBN genotype
that was associated with GF, suggesting involvement of local,
intra-renal pathways in processes of transplanted kidney survival
which are independent of systemic influences.
Albuminuria is known as a predictor of cardiovascular and non-
cardiovascular mortality [13]. However, in our study CUBN
genotypes did not associate with cerebro- or cardiovascular
accident as a cause of death in donors and cardiovascular and
all-cause mortality after transplantation in recipients.
Table 1. Main patients and transplantation-related
characteristics.
ESRD patients, n = 1141
Age, years 48.2613.5
Sex: male, n (%) 662 (58.0)
Primary disease:
- glomerulopathies, n (%) 292 (25.6)
- kidney cysts, n (%) 188 (16.5)
- tubulo-interstitial lesions, n (%) 135 (11.8)
- diabetes types I and II, n (%) 47 (4.1)
- renal hypoplasia, n (%) 23 (2.0)
- drug-induced nephritis, n (%) 15 (1.3)
- other/uncertain etiology, n (%) 488 (43)
Kidney donors, n= 1182
Age, years 44.5614.3
Sex: male, n (%) 603 (51.0)
Living donors, n (%) 282 (23.9)
- from which related donors, n (%) 164 (58.2)
Transplantation, n =962 renal transplant recipients
Cold ischemia time, minutes 1140 [869–1428]
Total warm ischemia time, minutes 40 [34–50]
Follow-up duration, years 5.8 [3.8–9.5]
Measured GFR at 1 year post-transplant, ml/min 54.8619.2
Total proteinuria at 1 year post-transplant, g/24 h 0.20 [0.05–0.40]
Acute rejection episodes history, n (%) 324 (33.7)
Graft failure, n (%) 92 (9.6)
Death with a functioning graft, n (%) 152 (15.8)
Continuous normally distributed variables are presented as mean6SD, non-
normally distributed – as median [IQR].
doi:10.1371/journal.pone.0036512.t001
Table 2. CUBN SNPs in the case-control study of ESRD patients versus kidney donors.
CUBN SNPs
ESRD patients,
n = 1141
Kidney donors,
n= 1182
OR [95% CI] per copy of the
minor allelea p valuea
rs7918972 Genotypes, count 21/301/819 12/246/924
MAF, % 15.0% 11.4% 1.39 [1.16–1.65] 0.0004
rs1801239 Genotypes, count 8/276/857 14/266/902
MAF, % 12.8% 12.4% 1.04 [0.87–1.24] 0.6686
OR, odds ratio; CI, confidence interval.
aLogistic regression model adjusted for age and sex, with adjustment for case-control relatedness (DFAM algorithm).
doi:10.1371/journal.pone.0036512.t002
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As no albuminuria data were available and urinary albumin
levels are known to correlate with total protein, we tested
association of the CUBN SNPs with 24-h total urinary protein
excretion as a surrogate phenotype. Interestingly, we found donor
rs7918972 to be associated with elevated proteinuria levels cross-
sectionally at 1 year after transplantation. This is consistent with
our results of association with the outcome, and also in line with
the results of a recent study which revealed, using exome
sequencing, a deleterious mutation in CUBN in a family of
proteinuric patients, thus confirming the CUBN gene involvement
in proteinuria [14].
In the original GWAS [4] the CUBN SNP rs1801239, associated
with elevated urinary albumine-to-creatinine ratio and microal-
buminuria. However, this SNP was not associated with CKD or
estimated GFR. In agreement with this, our case-control study
showed no association between this SNP and ESRD. Also,
rs1801239 was not associated with GF in our longitudinal study
Instead, it was the other CUBN polymorphism, the tagSNP
rs7918972, that was associated with ESRD in our study.
The CUBN locus is characterized by a high variability, with both
common and rare mutations. Mutations in the CUBN locus are
known to be the cause of Imerslund-Gra¨sbeck syndrome (OMIM
#261100, Finnish type) which is a rare (the estimated prevalence
is ,6:1,000,000) autosomal recessive disorder characterized by
vitamin B12 deficiency commonly resulting in megaloblastic
anemia, and also neurological damage and mild proteinuria
[15]. However, we did not aim to address previously clinically-
associated Mendelian mutations in the CUBN in our study. We
aimed to investigate whether common variation, as opposed to rare
mutations in Imerslund-Gra¨sbeck syndrome, in the CUBN
associates with kidney disease. In the same time, we targeted a
lower part of the common variability range, with MAFs between
10 and 15%, aiming to reveal allegedly stronger genetic effects.
We selected two SNPs in the CUBN locus for the present study:
first, the one previously published to be associated with
Table 3. Interaction between the SNPs in the CUBN locus in the case-control study of ESRD patients versus kidney donors.
CUBN SNPs rs7918972
N of the minor allele copies 0 1 or 2
Reference OR 0.93 [0.75–1.15]
0 OR 1.00 p= 0.484
rs1801239 n= 1352 n= 407
OR 0.65 [0.52–0.81] OR 3.15 [2.21–4.48]
1 or 2 p= 1.761024 p= 1.8610210
n = 391 n = 173
Logistic regression model adjusted for age and sex. Odds ratios (OR) [95% confidence intervals] for risk of ESRD, p-values and patients number (n) are presented in
relation to simultaneous presence of both minor alleles in genotype.
doi:10.1371/journal.pone.0036512.t003
Figure 2. Curves of long-term renal graft survival by donor rs7918972 genotype. Numbers 0 to 2 designate corresponding number of the
minor allele copies per genotype. The logrank test showed borderline statistical significance of the differences between the respective curves.
doi:10.1371/journal.pone.0036512.g002
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albuminuria levels in the general population, i.e. the missense
variant (Ile2984Val) rs1801239, and second the tagSNP in the
CUBN intron, rs7918972. The latter is in high linkage disequilib-
rium (r2 = 0.831) with another missense variant rs1801232
(Asn3552Lys) in CUBN, which might be responsible for the
biological impact of the polymorphism on the protein level. The
minor allele of rs1801232 leads to an asparagine-to-lysine amino
acid substitution in the C-terminal CUB27 domain of cubilin.
Despite the amino acids differ in chemical properties (isoelectric
points: Asn 5.4, Lys 9.8), the substitution was predicted to be
benign by bioinformatics algorithms. However, the mutation is
close to sites of N-glycosylation (amino acid 3533) and di-sulfide
bond (between amino acids 3564 and 3586) and therefore might
potentially interfere with secondary protein structure and,
consequently, function. The Imerslund-Gra¨sbeck syndrome mu-
tations, for which functionality was proven, affect the IF-
cobalamin-binding region in the CUB8 domain of cubilin
(rs121434430 Pro1297Leu), CUB6 domain (CUBN IVS6 C-G
in-frame insertion) or CUB23 domain (CUBN IVS23 G-T
transversion at the conserved donor splice site of exon 23). The
SNPs that we studied were spatially distant from these variants and
located to the CUB22 domain (rs1801239) and CUB27 domain
(rs1801232 tagged by rs7918972).
The rs7918972 CUBN SNP, associated with ESRD and GF in
our study, is localized in high proximity to the neighboring gene,
RSU1. Although the nine SNPs tagged by rs7918972 are all
located in the CUBN locus, linkage disequilibrium with and
involvement of the RSU1 is theoretically possible and cannot be
entirely ruled out (Suppl. Fig. S1). The RSU1 gene encodes Ras
suppressor protein 1, which participates in the Ras signal
transduction pathway, growth inhibition and nerve-growth factor
induced differentiation processes. Its mRNA is expressed in the
kidney (according to the NCBI GEO profiles), in a low-to-
moderate quantity (51 transcripts per million, according to the
NCBI EST profiles). However, functional proof is beyond the
scope of the present study, and further research will be needed to
discriminate between the effects of these neighboring genes.
Interestingly, we found an interaction between the two SNPs
studied. According to our data, the rs7918972 minor allele
requires a copy of the rs1801239 minor allele to express its risk
phenotype, whereas the minor allele of rs1801239 displays
protective effect in the absence of rs7918972 minor allele. This
pattern was observed in the case-control study and warrants
further investigation to determine whether found statistical
interaction has biological implications.
Our study was conducted in kidney transplant recipients, and
thus reflects a population that developed ESRD in their native
kidneys and was eligible to receive a transplantation. As such,
renal transplant recipients represent a relatively healthy subset of
the ESRD population, a selection bias inherent to any study in
renal transplantation. This should be considered a limitation to
our study. In chronic renal disease, both in native kidney disease
and in transplantation, mortality is high, and for analyses on
ESRD the competing risks of mortality, in particular cardiovas-
cular, are therefore relevant to consider. In the current population,
mortality with functioning graft was 15.8 percent, and no
association with either of the CUBN SNPs was observed.
Our longitudinal study of graft failure may have been
underpowered to detect a significant SNP effect. Insufficient
power might thus be an explanation of the fact that convincing
statistical significance was not reached in the graft survival analysis
for association with rs7918972. Studies in larger populations are
warranted to confirm an association between the CUBN SNP and
GF.
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Conclusion
Our study confirms association of the CUBN with renal
phenotypes of progressive renal function loss and urine protein
loss. We first identified CUBN SNP rs7918972 as a novel genetic
variant of susceptibility for ESRD in a case-control design. In a
separate proof-of-principle longitudinal study, which served as an
internal replication, we reproduced the association. Thus,
rs7918972 was associated with susceptibility to develop progressive
renal function loss in two settings, namely ESRD in native kidneys
and GF in transplanted kidneys. It was kidney genotype that
associated with increased risk, supporting impact of intra-renal
pathways on organ damage. Our study set-up – analyzing both
donor and recipient genotypes – provides a powerful design for
hypothesis-driven studies on risk loci for renal damage enabling
differentiation between local, intra-renal, and systemic, extra-
renal, influences.
Supporting Information
Figure S1 CUBN regional LD plot. The figure was generated
using HapMap data (release 22, CEU population). The horizontal
blue line represents an arbitrarily chosen LD threshold (r2 = 0.8).
SNPs are shown as diamonds. The color gradient between the
diamonds reflects the pairwise LD between the SNPs, with color
intensity of each diamond being directly proportional to the r2
value. Boundaries of the gene coding regions are shown as green
horizontal lines. The largest size diamonds represent the present
study SNPs. The shaded area designates a span of the gene region
tagged by rs7918972.
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